Lixte Biotechnology (NASDAQ:LIXT) Announces Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) released its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, Zacks reports.

Lixte Biotechnology Stock Up 0.5%

NASDAQ LIXT opened at $1.22 on Monday. Lixte Biotechnology has a 52 week low of $1.02 and a 52 week high of $3.50. The company has a market capitalization of $3.83 million, a P/E ratio of -0.70 and a beta of 0.40. The stock’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.72.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.